Clinical Outcomes Research
Our unique position in the outpatient infusion management setting, in collaboration with our physician partners, gives us unprecedented access to the highest quality real-world clinical data.
Our data warehouse is the largest in the outpatient infusion industry
Our data sets go way beyond simple claims data and provide evidence-based research in areas such as drug utilization, clinical outcomes and disease response, safety, health economic impacts, and persistence. The strength of our data allows us to collaborate with manufacturers and physicians to study novel therapies, compare treatment sites, and other cutting-edge research.
Clinical Outcomes
Cost Savings & Lower Resource Utilization
New Therapies and Programs
Persistance
Special Populations
Here is an example of one of our class-leading studies enabled by our data:
Click image to view full size
Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin, PharmD - Healix Infusion Therapy, Sugar Land, TX Claudia P. Schroeder, PharmD, PhD - Healix Infusion Therapy, Sugar Land, TX View Poster
Evaluation of Bezlotoxumab in Prevention of Recurrent C. Difficile Infection: A multicenter Single-Arm Study in Office Infusion Centers
Presented on October 3, 2018 Richard L. Hengel, MD Timothy E. Ritter, MD Ramesh V. Nathan, MD, FIDSA Lucinda J. Van Anglen, PharmD Stephen W. Marcella Kevin W. Garey, Pharm.D., M.S., FASHP View...
Healthcare Resource Utilization for High-Risk Patients Treated with Dalbavancin in Physician Office Infusion Centers
Presented on November 26, 2018 Authors: Quyen Luu, MD - Central Georgia Infectious Diseases Associates, Macon, GA Barry Statner, MD, FRCPC, FIDSA - Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA Robin H. Dretler, MD - Infectious Disease Specialists of...
Predictors of Vedolizumab Treatment Persistence in Bio-Naïve Ulcerative Colitis Patients
Timothy E. Ritter - GI Alliance, Southlake, TX Harry E. Sarles - Digestive Health Associates of Texas, Dallas, TX Samantha A. Mehta - Healix Infusion Therapy, Sugar Land, TX Lucinda J. Van Anglen - Healix Infusion Therapy, Sugar Land, TX View...
Real-World Prescribing Patterns of Certolizumab in the Treatment of Crohn’s Disease
Timothy E. Ritter, MD - GI Alliance, Southlake, TX Chris Fourment, MD - GI Alliance, Southlate, TX Samantha A. Kuten, PharmD - Healix Infusion Therapy, Sugar Land, TX Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX View...
Onset of Response with Infliximab vs. Vedolizumab in the Treatment of Bio-Naïve Inflammatory Bowel Disease
Chris Fourment - Texas Digestive Disease Consultants, PA, Southlake, TX Timothy E. Ritter - Texas Digestive Disease Consultants, PA, Southlake, TX Samantha A. Kuten - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin - Healix Infusion Therapy, Sugar Land, TX...
Second-Line Biologic Therapy After Vedolizumab
Timothy E. Ritter - Texas Digestive Disease Consulatants, PA, Southlake, TX Chris Fourment - Texas Digestive Disease Consulatants, PA, Southlake, TX Samantha A. Kuten - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin - Healix Infusion Therapy, Sugar Land,...
Long-Term Efficacy of Vedolizumab in Pediatric Inflammatory Bowel Disease
Selected as a Presidential Poster Harry E. Sarles - DHAT Research Institute, Richardson, TX Annette E. Whitney - Digestive Health Associates of Texas, Dallas, TX Samantha A. Kuten - Healix Infusion Therapy, Sugar Land, TX Lucinda J. Van Anglen - Healix Infusion...
Use of Ustekinumab in Pediatric Crohn’s Disease – A Report of Three Cases
Harry E. Sarles - DHAT Research Institute, Richardson, TX Annette E. Whitney - Digestive Health Associates of Texas, Dallas, TX Lucinda J. Van Anglen - Healix Infusion Therapy, Sugar Land, TX Samantha A. Kuten - Healix Infusion Therapy, Sugar Land, TX Thomas C....
Response and Healthcare Resource Utilization in Inflammatory Bowel Disease Patients Treated with Either Infliximab or Vedolizumab
Harry E. Sarles - DHAT Research Institute, Richardson, TX Thomas C. Hardin - Healix Infusion Therapy, Sugar Land, TX Samantha A. Kuten - Healix Infusion Therapy, Sugar Land, TX Lucinda J. Van Anglen - Healix Infusion Therapy, Sugar Land, TX View...
Low 30-Day Hospital Readmission Rates in Medicare Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers
Quyen Luu - Central Georgia Infectious Diseases, Macon, GA H. Barry Baker - Infectious Disease Physicians, Miami, FL Ramesh V. Nathan - Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA Richard L. Hengel - Atlanta ID Group, Atlanta, GA Alfred E. Bacon, III -...
Serious Bacterial Infections: Successful Outpatient Management by Infectious Disease Physicians in Office Infusion Centers
John S. Adams - Knoxville Infectious Disease Consultants, Knoxville, TN Brian S. Metzger - Austin Infectious Disease Consultants, Austin, TX Richard M. Mandel - Southern Arizona Infectious Disease Specialists, Tucson, AZ Thomas K. Sleweon - Infectious Disease...
Recurrent Clostridioides Difficile Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life
Kevin W. Garey - University of Houston College of Pharmacy, Houston, TX Claudia P. Schroeder - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin - Healix Infusion Therapy, Sugar Land, TX Richard L. Hengel - Atlanta ID Group, Atlanta, GA Timothy E. Ritter -...
Phase II and Phase III Studies
Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.
For information on partnering with Healix on a study, please contact us.